Predictors of treatment response to semaglutide for weight management
Open Access
- 17 September 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1893511
Abstract
The emergence of weekly, injectable glucagon-like peptide-1 (GLP-1) receptor agonists has revolutionized the obesity management landscape. Numerous studies have shown high efficacy as well as great variability in weight loss, highlighting the need for this mini review, summarizing current evidence about predictors of semaglutide-related weight loss. The first well-known determinant of semaglutide-induced weight loss is the presence of type 2 DM which is associated with significantly lower body weight reduction. The second predictor is sex, with females exhibiting a greater weight loss than males by a mean 6%. In addition, higher maintenance dose of 7.2 mg is superior to standard 2.4 mg dose in weight reduction by a mean 3%. There is no clear association of age and baseline body mass index with the magnitude of semaglutide-driven weight loss, except for the possibility of adolescence enhancing and overweight reducing this treatment effect. The potential impact of genetic polymorphisms of individual treatment response to semaglutide remains incompletely understood, limited so far to a modest effect of specific variants in GLP1 receptor gene. Another potential predictor of response could be obesity phenotype, with preliminary data supporting greater effectiveness of semaglutide in individuals with ‘‘hungry gut’’ phenotype. Type of lifestyle modification does not seem to have a significant effect on the variability of semaglutide-driven weight loss. Further studies are needed to expand knowledge about predictors of response to semaglutide, paving the way for validated predictive models in order to guide clinical decision-making and provision of personalized obesity care.Keywords
This publication has 48 references indexed in Scilit:
- The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist EraJAMA, 2026
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in AdultsJAMA Internal Medicine, 2026
- What to Know About the WHO’s New GLP-1 Drug GuidelineJAMA, 2026
- World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in AdultsJAMA, 2026
- Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and ObesityJAMA Psychiatry, 2025
- Changes in Adult Obesity Trends in the USJAMA Health Forum, 2024
- Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysisObesity, 2023
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity ClinicObesity, 2021